

The TGF- β paradox in human cancer: an update

Future Oncology

5, 259-271

DOI: [10.2217/14796694.5.2.259](https://doi.org/10.2217/14796694.5.2.259)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Eosinophils and Oral Squamous Cell Carcinoma: A Short Review. <i>Journal of Oncology</i> , 2009, 2009, 1-6.	0.6	28
2	p130Cas Is Required for Mammary Tumor Growth and Transforming Growth Factor- β -mediated Metastasis through Regulation of Smad2/3 Activity. <i>Journal of Biological Chemistry</i> , 2009, 284, 34145-34156.	1.6	62
3	Activated Abl kinase inhibits oncogenic transforming growth factor- β signaling and tumorigenesis in mammary tumors. <i>FASEB Journal</i> , 2009, 23, 4231-4243.	0.2	56
4	Induction of endometrial epithelial cell invasion and c-fms expression by transforming growth factor beta. <i>Molecular Human Reproduction</i> , 2009, 15, 665-673.	1.3	30
5	Less Smad2 is good for you! A scientific update on coffee's liver benefits. <i>Hepatology</i> , 2009, 50, 970-978.	3.6	26
6	SPARC: a matricellular regulator of tumorigenesis. <i>Journal of Cell Communication and Signaling</i> , 2009, 3, 255-273.	1.8	147
7	Role of transforming growth factor β in cancer microenvironment. <i>Clinical and Translational Oncology</i> , 2009, 11, 715-720.	1.2	27
8	CLU and Out: Advances in Cancer Research, 2009, 105, 93-113.	1.9	25
9	Inhibiting Breast Cancer Progression by Exploiting TGF β Signaling. <i>Current Drug Targets</i> , 2010, 11, 1089-1102.	1.0	5
10	The Pathophysiology of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor- β in Normal and Malignant Mammary Epithelial Cells. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2010, 15, 169-190.	1.0	202
11	Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGF β signaling pathway in SW480 cells. <i>Biochemical Pharmacology</i> , 2010, 80, 2057-2065.	2.0	221
12	Kinases as targets in the treatment of solid tumors. <i>Cellular Signalling</i> , 2010, 22, 984-1002.	1.7	88
13	An efficient method for expression in <i>Escherichia coli</i> and purification of the extracellular ligand binding domain of the human TGF β type II receptor. <i>Journal of Biotechnology</i> , 2010, 148, 113-118.	1.9	5
14	JAB1/CSN5: a new player in cell cycle control and cancer. <i>Cell Division</i> , 2010, 5, 26.	1.1	132
15	Radiation Resistance of Cancer Stem Cells: The 4 R's of Radiobiology Revisited. <i>Stem Cells</i> , 2010, 28, 639-648.	1.4	328
16	Pilot analysis of cytokines levels in stored granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell concentrates. <i>Transfusion</i> , 2010, 50, 2011-2015.	0.8	7
17	The primary mitogen (TCPOBOP)-induced hepatocyte proliferation is resistant to transforming growth factor- β -1 inhibition. <i>Liver International</i> , 2010, 30, 1505-1510.	1.9	1
18	Transforming growth factor- β -induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. <i>Oncogene</i> , 2010, 29, 6485-6498.	2.6	173

#	ARTICLE	IF	CITATIONS
19	The tumour suppressor C/EBP β inhibits FBXW7 expression and promotes mammary tumour metastasis. <i>EMBO Journal</i> , 2010, 29, 4106-4117.	3.5	95
20	The polarization of immune cells in the tumour environment by TGF β ² . <i>Nature Reviews Immunology</i> , 2010, 10, 554-567.	10.6	795
21	Reporter Gene Imaging of Cell Signal Transduction. , 0, , 195-226.		0
22	New Medical Strategies for Midgut Carcinoids. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 250-269.	0.9	8
23	The Tumor-Suppressive Function of Connexin43 in Keratinocytes Is Mediated in Part via Interaction with Caveolin-1. <i>Cancer Research</i> , 2010, 70, 4222-4232.	0.4	63
24	PGE2 receptor EP2 mediates the antagonistic effect of COX β on TGF β ² signaling during mammary tumorigenesis. <i>FASEB Journal</i> , 2010, 24, 1105-1116.	0.2	62
25	Signal Transducer and Activator of Transcription (STAT)-5A and STAT5B Differentially Regulate Human Mammary Carcinoma Cell Behavior. <i>Endocrinology</i> , 2010, 151, 43-55.	1.4	48
26	Androgen Regulation of Gene Expression. <i>Advances in Cancer Research</i> , 2010, 107, 137-162.	1.9	97
27	TGF- β ² signaling in aortic aneurysm: another round of controversy. <i>Journal of Genetics and Genomics</i> , 2010, 37, 583-591.	1.7	23
28	Role of Cripto-1 in Stem Cell Maintenance and Malignant Progression. <i>American Journal of Pathology</i> , 2010, 177, 532-540.	1.9	110
29	An integrative view on the role of TGF- β ² in the progressive tubular deletion associated with chronic kidney disease. <i>Kidney International</i> , 2010, 77, 950-955.	2.6	131
30	Hepatocellular Carcinoma Cells and Their Fibrotic Microenvironment Modulate Bone Marrow-Derived Mesenchymal Stromal Cell Migration <i>in Vitro</i> and <i>in Vivo</i> . <i>Molecular Pharmaceutics</i> , 2011, 8, 1538-1548.	2.3	72
31	Lysyl Oxidase Contributes to Mechanotransduction-Mediated Regulation of Transforming Growth Factor- β ² Signaling in Breast Cancer Cells. <i>Neoplasia</i> , 2011, 13, 406-IN2.	2.3	85
32	Alcohol, Cancer Genes, and Signaling Pathways. , 2011, , 93-126.		1
33	TGF- β ² and Restenosis Revisited: A Smad Link. <i>Journal of Surgical Research</i> , 2011, 167, 287-297.	0.8	51
34	Resveratrol, MicroRNAs, Inflammation, and Cancer. <i>Journal of Nucleic Acids</i> , 2011, 2011, 1-9.	0.8	80
35	Role of TGF- β ² and the Tumor Microenvironment During Mammary Tumorigenesis. <i>Gene Expression</i> , 2011, 15, 117-132.	0.5	81
36	Association between brain natriuretic peptide and distant metastases in advanced non-small cell lung cancer patients. <i>Oncology Letters</i> , 2011, 2, 253-256.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Noncanonical TGF- β 2 Signaling During Mammary Tumorigenesis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 127-146.	1.0	103
38	Inducible expression of TGF β 2, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 593-614.	1.7	59
39	MicroRNA Dysregulation in Colon Cancer Microenvironment Interactions: The Importance of Small Things in Metastases. <i>Cancer Microenvironment</i> , 2011, 4, 155-162.	3.1	16
40	Mechanisms of transforming growth factor β 2 induced cell cycle arrest in palate development. <i>Journal of Cellular Physiology</i> , 2011, 226, 1415-1424.	2.0	44
41	Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth in Mice through the Antiproliferative Activity of TGF β 2. <i>Cancer Research</i> , 2011, 71, 3306-3316.	0.4	66
42	Pleiotropic functions of EAPII/TTRAP/TDP2. <i>Cell Cycle</i> , 2011, 10, 3274-3283.	1.3	25
43	NetSlim: high-confidence curated signaling maps. Database: the <i>Journal of Biological Databases and Curation</i> , 2011, 2011, bar032-bar032.	1.4	29
44	Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. <i>Carcinogenesis</i> , 2011, 32, 1050-1056.	1.3	32
45	The Cain and Abl of Epithelial-Mesenchymal Transition and Transforming Growth Factor- β 2 in Mammary Epithelial Cells. <i>Cells Tissues Organs</i> , 2011, 193, 98-113.	1.3	22
46	Growth Factors in Induction of Epithelial-Mesenchymal Transition and Metastasis. <i>Cells Tissues Organs</i> , 2011, 193, 85-97.	1.3	73
47	Fibromodulin Suppresses Nuclear Factor- κ B Activity by Inducing the Delayed Degradation of IKBA via a JNK-dependent Pathway Coupled to Fibroblast Apoptosis. <i>Journal of Biological Chemistry</i> , 2011, 286, 6414-6422.	1.6	28
48	Prognostic value of transforming growth factor beta 1 [TGF- β 1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. <i>Biomarkers</i> , 2012, 17, 21-27.	0.9	34
49	SnoN regulates mammary gland alveologenesis and onset of lactation by promoting prolactin/Stat5 signaling. <i>Development (Cambridge)</i> , 2012, 139, 3147-3156.	1.2	24
50	Raf-1, a Potential Therapeutic Target, Mediates Early Steps in Endometriosis Lesion Development by Endometrial Epithelial and Stromal Cells. <i>Endocrinology</i> , 2012, 153, 3911-3921.	1.4	12
51	Integrin β 4 Regulates SPARC Protein to Promote Invasion. <i>Journal of Biological Chemistry</i> , 2012, 287, 9835-9844.	1.6	41
52	Analysis of Gene Expression Regulated by the <i>ETV5</i> Transcription Factor in OV90 Ovarian Cancer Cells Identifies <i>FOXM1</i> Overexpression in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2012, 10, 914-924.	1.5	22
53	Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2184-2220.	0.9	29
54	Microenvironmental Regulation of Cancer Stem Cell Phenotypes. <i>Current Stem Cell Research and Therapy</i> , 2012, 7, 197-216.	0.6	93

#	ARTICLE	IF	CITATIONS
55	IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. <i>Oncology Letters</i> , 2012, 4, 199-204.	0.8	34
56	Coffee and Caffeine Protect against Liver Injury Induced by Thioacetamide in Male Wistar Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 339-347.	1.2	71
57	The miR-106b-25 cluster targets Smad7, activates TGF- β 2 signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. <i>Oncogene</i> , 2012, 31, 5162-5171.	2.6	276
58	Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice. <i>Hepatology</i> , 2012, 56, 1924-1933.	3.6	49
59	Germline prognostic markers for urinary bladder cancer: Obstacles and opportunities. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 524-532.	0.8	21
60	Characterization of a cell culture model for clinically aggressive hepatocellular carcinoma induced by chronic hypoxia. <i>Cancer Letters</i> , 2012, 315, 178-188.	3.2	12
61	Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor- β 2 pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10978-10983.	3.3	117
62	Digitoxin and its analogs as novel cancer therapeutics. <i>Experimental Hematology and Oncology</i> , 2012, 1, 4.	2.0	96
63	The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 455-467.	2.7	97
64	Lewis Y regulates signaling molecules of the transforming growth factor β 2 pathway in ovarian carcinoma-derived RMG-I cells. <i>International Journal of Oncology</i> , 2012, 40, 1196-1202.	1.4	15
65	Molecular Pathways: Targeting the TGF- β 2 Pathway for Cancer Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 4514-4521.	3.2	172
66	CD4 ⁺ CD25 ^{high} Foxp3 ⁺ Cells Increased in the Peritoneal Fluid of Patients with Endometriosis. <i>American Journal of Reproductive Immunology</i> , 2012, 68, 301-308.	1.2	67
67	Induction of palate epithelial mesenchymal transition by transforming growth factor β 3 signaling. <i>Development Growth and Differentiation</i> , 2012, 54, 633-648.	0.6	35
68	Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. <i>Hepatology</i> , 2012, 55, 121-131.	3.6	56
69	Transforming growth factor- β 2 and atherosclerosis: interwoven atherogenic and atheroprotective aspects. <i>Cell and Tissue Research</i> , 2012, 347, 155-175.	1.5	205
70	Deconstructing the mechanisms and consequences of TGF- β 2-induced EMT during cancer progression. <i>Cell and Tissue Research</i> , 2012, 347, 85-101.	1.5	202
71	Role of TGF- β 2 in chronic kidney disease: an integration of tubular, glomerular and vascular effects. <i>Cell and Tissue Research</i> , 2012, 347, 141-154.	1.5	250
72	Diet-induced obesity and ethanol impair progression of hepatocellular carcinoma in a mouse mesenteric vein injection model. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 246-255.	1.3	13

#	ARTICLE	IF	CITATIONS
73	Canonical TGF- β Pathway Activity Is a Predictor of SHH-Driven Medulloblastoma Survival and Delineates Putative Precursors in Cerebellar Development. <i>Brain Pathology</i> , 2013, 23, 178-191.	2.1	26
74	Nodal signalling in embryogenesis and tumourigenesis. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 885-898.	1.2	77
75	p130Cas controls the susceptibility of cancer cells to TGF- β -induced growth inhibition. <i>Biochemical and Biophysical Research Communications</i> , 2013, 438, 116-121.	1.0	4
76	Transforming Growth Factor β 1 Signal is Crucial for Dedifferentiation of Cancer Cells to Cancer Stem Cells in Osteosarcoma. <i>Stem Cells</i> , 2013, 31, 433-446.	1.4	102
77	The relevance of the TGF- β Paradox to EMT-MET programs. <i>Cancer Letters</i> , 2013, 341, 30-40.	3.2	174
78	TCTEX1D4, a novel protein phosphatase 1 interactor: connecting the phosphatase to the microtubule network. <i>Biology Open</i> , 2013, 2, 453-465.	0.6	17
79	Intestinal GUCY2C Prevents TGF- β Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer. <i>Cancer Research</i> , 2013, 73, 6654-6666.	0.4	21
80	Reduction of prostate cancer incidence by naftopidil, an α -adrenoceptor antagonist and transforming growth factor- β signaling inhibitor. <i>International Journal of Urology</i> , 2013, 20, 1220-1227.	0.5	30
81	Epigenetic regulation of <i>DACH1</i> , a novel Wnt signaling component in colorectal cancer. <i>Epigenetics</i> , 2013, 8, 1373-1383.	1.3	79
82	Immunological effects of the TGF- β -blocking antibody GC1008 in malignant pleural mesothelioma patients. <i>Oncolmmunology</i> , 2013, 2, e26218.	2.1	68
83	The Many Faces of C/EBP β and their Relevance for Inflammation and Cancer. <i>International Journal of Biological Sciences</i> , 2013, 9, 917-933.	2.6	127
84	Silencing DACH1 Promotes Esophageal Cancer Growth by Inhibiting TGF- β Signaling. <i>PLoS ONE</i> , 2014, 9, e95509.	1.1	26
85	Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial \rightarrow mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15526-15531.	3.3	178
86	Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology. <i>Journal of Clinical Pathology</i> , 2014, 67, 1026-1031.	1.0	33
87	TGF- β -mediated suppression of CD248 in non-cancer cells via canonical Smad-dependent signaling pathways is uncoupled in cancer cells. <i>BMC Cancer</i> , 2014, 14, 113.	1.1	13
88	Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean <i>in silico</i> model. <i>Molecular Oncology</i> , 2014, 8, 351-365.	2.1	74
89	TGF- β -Mediated Suppression of CD248 in Non-Cancer Cells via Canonical SMAD-Dependent Signaling Pathways is Uncoupled in Cancer Cells. , 2014, , 1-26.		0
90	Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor- β signaling pathway. <i>OncoTargets and Therapy</i> , 2015, 8, 1553.	1.0	26

#	ARTICLE	IF	CITATIONS
91	Ubiquitin specific protease 22 promotes cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth factor β 1. <i>Oncology Reports</i> , 2015, 33, 133-140.	1.2	17
92	Transforming growth factor- β 2 promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. <i>Oncogene</i> , 2015, 34, 4767-4776.	2.6	81
93	TSC1 Activates TGF- β 2-Smad2/3 Signaling in Growth Arrest and Epithelial-to-Mesenchymal Transition. <i>Developmental Cell</i> , 2015, 32, 617-630.	3.1	54
94	Relationships Between SMAD3 Expression and Preoperative Fluoropyrimidine-Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients. <i>World Journal of Surgery</i> , 2015, 39, 1257-1267.	0.8	9
95	Waltonitone induces apoptosis through mir-663-induced Bcl-2 downregulation in non-small cell lung cancer. <i>Tumor Biology</i> , 2015, 36, 871-876.	0.8	10
96	Deptor Enhances Triple-Negative Breast Cancer Metastasis and Chemoresistance through Coupling to Survivin Expression. <i>Neoplasia</i> , 2015, 17, 317-328.	2.3	58
97	Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology. <i>Postgraduate Medical Journal</i> , 2015, 91, 291-296.	0.9	2
98	Genetic instability in the tumor microenvironment: a new look at an old neighbor. <i>Molecular Cancer</i> , 2015, 14, 145.	7.9	48
99	Growth factors in fetal and adult wound healing. , 2016, , 41-68.		2
100	miR-663 overexpression induced by endoplasmic reticulum stress modulates hepatocellular carcinoma cell apoptosis via transforming growth factor beta 1. <i>OncoTargets and Therapy</i> , 2016, 9, 1623.	1.0	29
101	Dichotomous roles of TGF- β 2 in human cancer. <i>Biochemical Society Transactions</i> , 2016, 44, 1441-1454.	1.6	91
102	Molecular biology of gynecological cancer. <i>Oncology Letters</i> , 2016, 11, 16-22.	0.8	16
103	The paradoxical functions of EGFR during breast cancer progression. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, .	7.1	95
104	Dual function of TGF β 2 in lens epithelial cell fate: implications for secondary cataract. <i>Molecular Biology of the Cell</i> , 2017, 28, 907-921.	0.9	39
105	Downregulation of delta-aminolevulinic acid dehydratase is associated with poor prognosis in patients with breast cancer. <i>Cancer Science</i> , 2017, 108, 604-611.	1.7	22
106	TGF- β 2 in Development and Ageing. <i>Healthy Ageing and Longevity</i> , 2017, , 127-148.	0.2	0
107	Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. <i>Science Signaling</i> , 2017, 10, .	1.6	52
108	Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling. <i>Frontiers in Pharmacology</i> , 2017, 8, 153.	1.6	23

#	ARTICLE	IF	CITATIONS
109	Mammary Gland Involution Provides a Unique Model to Study the TGF- β 2 Cancer Paradox. <i>Journal of Clinical Medicine</i> , 2017, 6, 10.	1.0	24
110	Fractalkine. , 2018, , 1867-1867.		0
111	Fused. , 2018, , 1875-1875.		0
112	The concomitant apoptosis and EMT underlie the fundamental functions of TGF- β 2. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 91-97.	0.9	31
113	Immune cell expression of TGF- β 21 in cancer with lymphoid stroma: dendritic cell and regulatory T cell contact. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 1021-1028.	1.4	5
114	<sc>TGF</sc>- β 2 transactivates <sc>EGFR</sc> and facilitates breast cancer migration and invasion through canonical Smad3 and <sc>ERK</sc>/Sp1 signaling pathways. <i>Molecular Oncology</i> , 2018, 12, 305-321.	2.1	111
115	miR-663a inhibits tumor growth and invasion by regulating TGF- β 21 in hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 1179.	1.1	28
116	An Improved Method for Prediction of Cancer Prognosis by Network Learning. <i>Genes</i> , 2018, 9, 478.	1.0	33
117	Nuclear PKM2 promotes the progression of oral squamous cell carcinoma by inducing EMT and post-translationally repressing TGIF2. <i>Oncotarget</i> , 2018, 9, 33745-33761.	0.8	28
118	The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 450.	1.8	13
119	Blockade of TGF- β 2 signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25 β Foxp3+ T cells. <i>Journal of Translational Medicine</i> , 2019, 17, 219.	1.8	36
120	Phytochemical Modulation of MiRNAs in Colorectal Cancer. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 48.	0.7	9
121	TGF beta promotes repair of bulky DNA damage through increased ERCC1/XPF and ERCC1/XPA interaction. <i>Carcinogenesis</i> , 2019, 40, 580-591.	1.3	20
122	Scarless wound healing: From development to senescence. <i>Advanced Drug Delivery Reviews</i> , 2019, 146, 325-343.	6.6	59
123	A Proliferation-Inducing Ligand Regulation in Polymorphonuclear Neutrophils by Panax ginseng. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 32.	1.0	2
124	Heterofusion: Fusing genomics data of different measurement scales. <i>Journal of Chemometrics</i> , 2021, 35, e3200.	0.7	5
126	Assessment of the Role of Selected SMAD3 and SMAD4 Genes Polymorphisms in the Development of Colorectal Cancer: Preliminary Research. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 167-178.	0.4	4
127	What deubiquitinating enzymes, oncogenes, and tumor suppressors actually do: Are current assumptions supported by patient outcomes?. <i>BioEssays</i> , 2021, 43, e2000269.	1.2	3

#	ARTICLE	IF	CITATIONS
128	bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	1.4	81
129	MicroRNAs and Natural Compounds Mediated Regulation of TGF Signaling in Prostate Cancer. Frontiers in Pharmacology, 2020, 11, 613464.	1.6	6
130	Inhibitors of TGF β 2R1/ALK4/JNK3/Flt1 Kinases in Cynomolgus Macaques Lead to the Rapid Induction of Renal Epithelial Tumors. Toxicological Sciences, 2021, 180, 51-61.	1.4	1
131	Actin Cytoskeleton and Regulation of TGF β 2 Signaling: Exploring Their Links. Biomolecules, 2021, 11, 336.	1.8	17
132	Ameliorative effects of colostrum against DMBA hepatotoxicity in rats. Saudi Journal of Biological Sciences, 2021, 28, 2254-2266.	1.8	6
133	Melanoma-associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target*. British Journal of Dermatology, 2021, 185, 294-301.	1.4	7
134	The Role of TGF- β 2 Signaling Pathways in Cancer and Its Potential as a Therapeutic Target. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-16.	0.5	18
135	The Role of WAVE2 Signaling in Cancer. Biomedicines, 2021, 9, 1217.	1.4	13
136	Discovery and biological evaluation of phthalazines as novel non-kinase TGF β 2 pathway inhibitors. European Journal of Medicinal Chemistry, 2021, 223, 113660.	2.6	2
137	Antibody-Targeted Nanoparticles for Cancer Treatment. , 2020, , 35-65.		3
138	MED15, transforming growth factor beta 1 (TGF- β 2), Fc γ RIII (CD16), and HNK-1 (CD57) are prognostic biomarkers of oral squamous cell carcinoma. Scientific Reports, 2020, 10, 8475.	1.6	6
139	TGF- β 2 in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. Journal of Clinical Investigation, 2010, 120, 403-406.	3.9	102
140	Novel Genes and Pathways Modulated by Syndecan-1: Implications for the Proliferation and Cell-Cycle Regulation of Malignant Mesothelioma Cells. PLoS ONE, 2012, 7, e48091.	1.1	41
141	The Transcription Factor GLI1 Mediates TGF β 21 Driven EMT in Hepatocellular Carcinoma via a SNAI1-Dependent Mechanism. PLoS ONE, 2012, 7, e49581.	1.1	68
142	Biomarkers of TGF- β 2 Signaling Pathway and Prognosis of Pancreatic Cancer. PLoS ONE, 2014, 9, e85942.	1.1	99
143	Targeting the TGF β 2 pathway in uterine carcinosarcoma. Cell Stress, 2020, 4, 252-260.	1.4	7
144	Characterization of the tumor cell microenvironment. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 67.	0.0	11
145	Chamaejasmenin B, a novel candidate, inhibits breast tumor metastasis by rebalancing TGF-beta paradox. Oncotarget, 2016, 7, 48180-48192.	0.8	30

#	ARTICLE	IF	CITATIONS
146	Sphingosine kinase 1 is required for TGF- β 2 mediated fibroblast-to-myofibroblast differentiation in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 4167-4182.	0.8	51
147	TGF- β 2 stimulation of EMT programs elicits non-genomic ER- α activity and anti-estrogen resistance in breast cancer cells. <i>Journal of Cancer Metastasis and Treatment</i> , 2017, 3, 150.	0.5	43
148	Profiling of Gene Expression Associated with Stemness and Aggressiveness of ALDH1A1-Expressing Human Breast Cancer Cells. <i>The Malaysian Journal of Medical Sciences</i> , 2019, 26, 38-52.	0.3	5
149	Transforming Growth Factor-Beta1 and Myeloid-Derived Suppressor Cells Interplay in Cancer. <i>The Open Cancer Immunology Journal</i> , 2017, 6, 1-14.	0.2	5
150	Identification of Paraxanthine as the Most Potent Inhibitor of TGF- β 2 Dependent Connective Tissue Growth Factor Expression Among the Three Primary Caffeine Metabolites - A New Approach in the Pharmacological Management of Chronic Fibrogenic Diseases?. <i>The Open Conference Proceedings Journal</i> , 2010, 1, 239-250.	0.6	1
151	Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. <i>World Journal of Gastroenterology</i> , 2017, 23, 2276.	1.4	13
152	Mass spectrometry-based iTRAQ analysis of serum markers in patients with pancreatic cancer. <i>Oncology Letters</i> , 2020, 19, 4106-4114.	0.8	4
153	TGF- β 2 Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. <i>Cancer Research and Treatment</i> , 1970, 47, 101-109.	1.3	13
154	Clinically Translatable Approaches of Inhibiting TGF- β 2 to Target Cancer Stem Cells in TNBC. <i>Biomedicines</i> , 2021, 9, 1386.	1.4	14
155	Dormancy of Disseminated Tumor Cells: Reciprocal Crosstalk with the Microenvironment. , 2010, , 229-254.		0
157	Fibulins. , 2012, , 616-623.		0
158	Response of Fetal and Adult Cells to Growth Factors. , 2013, , 65-77.		0
159	The Multifunctional Roles of TGF- β 2 in Navigating the Metastatic Cascade. , 2013, , 169-187.		0
160	Fibulins. , 2018, , 1723-1730.		0
161	Transforming Growth Factor Beta (TGF- β 2) Signaling in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Cancer Research</i> , 2018, , 89-115.	0.2	0
162	Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). <i>Molecular Medicine Reports</i> , 2019, 20, 1488-1498.	1.1	10
163	Differentiation plasticity of human monocytes in culture. , 2020, 11, 1-10.	0.0	0
164	How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 53, 116534.	1.4	7

#	ARTICLE	IF	CITATIONS
165	Identification of Prognostic Gene Biomarkers in Non-Small Cell Lung Cancer Progression by Integrated Bioinformatics Analysis. <i>Biology</i> , 2021, 10, 1200.	1.3	16
166	Targeted Deletion of Kindlin-2 in Mouse Mammary Glands Inhibits Tumor Growth, Invasion, and Metastasis Downstream of a TGF- β 2/EGF Oncogenic Signaling Pathway. <i>Cancers</i> , 2022, 14, 639.	1.7	4
167	Mammalian tumor-like organs. 1. The role of tumor-like normal organs and atypical tumor organs in the evolution of development (carcino-evo-devo). <i>Infectious Agents and Cancer</i> , 2022, 17, 2.	1.2	4
168	Plasma Growth Factor Gene Expression and Mammographic Breast Density in Postmenopausal Women. <i>Cancer Prevention Research</i> , 2022, 15, 391-398.	0.7	1
169	Paradoxical Behavior of Oncogenes Undermines the Somatic Mutation Theory. <i>Biomolecules</i> , 2022, 12, 662.	1.8	9
170	The roles of TGF- β 2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
171	Investigation of the protective and therapeutic effects of <i>Lactobacillus casei</i> and <i>Saccharomyces cerevisiae</i> in a breast cancer mouse model. <i>AIMS Microbiology</i> , 2022, 8, 193-207.	1.0	0
172	Deep learning for de-convolution of Smad2 versus Smad3 binding sites. <i>BMC Genomics</i> , 2022, 23, .	1.2	1
173	Clinical and Histopathological Factors Associated with the Tumoral Expression of TGF- β 21, MED15, CD16, and CD57 in Oral Squamous Cell Carcinoma. <i>Advances in Preventive Medicine</i> , 2022, 2022, 1-11.	1.1	1
174	Roles of TGF- β 2 in cancer hallmarks and emerging onco-therapeutic design. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, .	1.6	2
176	Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGF β 2 and PD-1/PD-L1. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1187-1202.	1.9	1
177	Epithelial to Mesenchymal Transition Induced in Cancer Cells by Adhesion to Type I Collagen. <i>International Journal of Molecular Sciences</i> , 2023, 24, 198.	1.8	2
178	Transforming growth factor- β 2 mediated regulation of epigenome is required for epithelial to mesenchymal transition associated features in liver cancer cells. <i>Heliyon</i> , 2023, 9, e14665.	1.4	1
179	TGF- β 2 mediated drug resistance in solid cancer. <i>Cytokine and Growth Factor Reviews</i> , 2023, 71-72, 54-65.	3.2	9
180	Common Attractors in Multiple Boolean Networks. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2023, , 1-12.	1.9	0
184	TGF- β 2 in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer. , 2023, 40, .		1